Associated Papers
Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients.
Shenoy PV et al.
Cancer Metastasis Reviews, 2025
Relevance of selected pharmacogenetic polymorphisms to bleeding and thromboembolic risks in Chinese patients taking direct-acting oral anticoagulants.
Wang D et al.
British Journal of Clinical Pharmacology, 2025
Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influence on tacrolimus dose adjusted concentrations in adult heart transplant recipients.
Liu M et al.
The Pharmacogenomics Journal, 2024
Characterization of Reference Materials for CYP3A4 and CYP3A5: A (GeT-RM) Collaborative Project.
Gaedigk A et al.
The Journal of Molecular Diagnostics : Jmd, 2023
CYP3A4 and CYP3A5 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2023
Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influences on tacrolimus dose adjusted concentration in adult heart transplant recipients.
Hernandez S et al.
Research Square, 2023
Cyp3A4 *1G polymorphism is associated with alcohol drinking: A 5-year retrospective single centered population-based study in China.
Jia X et al.
Plos One, 2023
Polymorphisms in drug metabolism genes predict the risk of refractory myasthenia gravis.
Zhang Q et al.
Annals of Translational Medicine, 2022
Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44.
Sohn SH et al.
Cancers, 2022
Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity.
Zhai Q et al.
Frontiers in Pharmacology, 2022
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
Clinical Relevance of a 16-Gene Pharmacogenetic Panel Test for Medication Management in a Cohort of 135 Patients.
Niedrig DF et al.
Journal of Clinical Medicine, 2021
Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
Stäuble CK et al.
International Journal of Molecular Sciences, 2021
Genetic polymorphisms of high platelet reactivity in Chinese patients with coronary heart disease under clopidogrel therapy.
Zou X et al.
International Journal of Clinical Pharmacy, 2020
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI.
Claassens DMF et al.
The New England Journal of Medicine, 2019
Aspirin & clopidogrel non-responsiveness & its association with genetic polymorphisms in patients with myocardial infarction.
Pandey CP et al.
The Indian Journal of Medical Research, 2019
Association between CYP2C19*2/*3 Polymorphisms and Coronary Heart Disease.
Zhang YY et al.
Current Medical Science, 2019
Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.
Mahdieh N et al.
Cardiovascular Toxicology, 2018
CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention.
Mohammad AM et al.
Journal of Cardiovascular Pharmacology, 2018
The influence of ABCB1 and P2Y12 genetic variants on clinical outcomes in Chinese intracranial artery stenosis patients.
Li X et al.
Clinical and Experimental Pharmacology & Physiology, 2018
The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
Saydam F et al.
Basic & Clinical Pharmacology & Toxicology, 2017
Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel.
Danielak D et al.
European Journal of Drug Metabolism and Pharmacokinetics, 2017
Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis.
Zhao Z et al.
European Journal of Clinical Pharmacology, 2016
Analysis of variants in the HCN4 gene and in three single nucleotide polymorphisms of the CYP3A4 gene for association with ivabradine reduction in heart rate: A preliminary report.
Núñez L et al.
Cardiology Journal, 2016
Sex Steroid Hormone Single-Nucleotide Polymorphisms, Pesticide Use, and the Risk of Prostate Cancer: A Nested Case-Control Study within the Agricultural Health Study.
Christensen CH et al.
Frontiers in Oncology, 2016
Genotyping of CYP2C19 polymorphisms and its clinical validation in the ethnic Arab population.
Tayeb HT et al.
The Journal of Pharmacy and Pharmacology, 2015
Allele frequency distribution of CYP2C19*2 allelic variants associated with clopidogrel resistance in cardiac patients.
Rehman KU et al.
Experimental and Therapeutic Medicine, 2015
Korean, Japanese, and Chinese populations featured similar genes encoding drug-metabolizing enzymes and transporters: a DMET Plus microarray assessment.
Yi S et al.
Pharmacogenetics and Genomics, 2014
Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy.
He XJ et al.
Epilepsia, 2014
The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese Han patients with coronary heart disease.
He BX et al.
Journal of Clinical Pharmacology, 2014
Influence of genetic variations on levels of inflammatory markers of healthy subjects at baseline and one week after clopidogrel therapy; results of a preliminary study.
Shahabi P et al.
International Journal of Molecular Sciences, 2013
Genetic determinants of clopidogrel responsiveness in Koreans treated with drug-eluting stents.
Park JJ et al.
International Journal of Cardiology, 2013
CYP3A4 genetic status may be associated with increased vulnerability to the inhibitory effect of calcium-channel blockers on clopidogrel.
Park JJ et al.
Circulation Journal : Official Journal of the Japanese Circulation Society, 2013
Relationship of CYP2C19*2 and CYP2C19*3 gene polymorphism with clopidogrel response variability and recurrent cardiovascular events in Chinese patients undergoing percutaneous coronary intervention.
Liu Y et al.
Pharmacology, 2013
Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China.
Meng XG et al.
Acta Pharmacologica Sinica, 2012
Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.
Gong IY et al.
European Heart Journal, 2012
Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients.
Zhong SL et al.
Pharmacogenetics and Genomics, 2012
High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers.
Marcucci R et al.
Platelets, 2012
Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics.
Visscher H et al.
Journal of Cardiovascular Pharmacology, 2011
Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond.
Xie HG et al.
Pharmacology & Therapeutics, 2011
Enhanced clopidogrel responsiveness in smokers: smokers' paradox is dependent on cytochrome P450 CYP1A2 status.
Park KW et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2011
A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population.
He BX et al.
Basic & Clinical Pharmacology & Toxicology, 2011
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study.
Harmsze AM et al.
European Heart Journal, 2010
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.
Sorich MJ et al.
Journal of Thrombosis and Haemostasis : Jth, 2010
Platelet pharmacogenomics.
Zuern CS et al.
Journal of Thrombosis and Haemostasis : Jth, 2010
Implications of Inter-Individual Differences in Clopidogrel Metabolism, with Focus on Pharmacogenetics.
Dahl ML et al.
Pharmaceuticals (basel, Switzerland), 2010
Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel.
Ma TK et al.
Pharmacology & Therapeutics, 2010
Pharmacogenetics in cardiovascular antithrombotic therapy.
Marín F et al.
Journal of the American College of Cardiology, 2009
Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan.
Jinnai T et al.
Circulation Journal : Official Journal of the Japanese Circulation Society, 2009